[go: up one dir, main page]

WO2000028999A3 - Procedes de traitement de la dyskinesie tardive et d'autres troubles moteurs - Google Patents

Procedes de traitement de la dyskinesie tardive et d'autres troubles moteurs Download PDF

Info

Publication number
WO2000028999A3
WO2000028999A3 PCT/US1999/027343 US9927343W WO0028999A3 WO 2000028999 A3 WO2000028999 A3 WO 2000028999A3 US 9927343 W US9927343 W US 9927343W WO 0028999 A3 WO0028999 A3 WO 0028999A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
movement disorders
tardive dyskinesia
agent
magnesium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/027343
Other languages
English (en)
Other versions
WO2000028999A2 (fr
Inventor
Barry S Fogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synchroneuron Inc
Original Assignee
Synchroneuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synchroneuron Inc filed Critical Synchroneuron Inc
Priority to AU17347/00A priority Critical patent/AU1734700A/en
Publication of WO2000028999A2 publication Critical patent/WO2000028999A2/fr
Publication of WO2000028999A3 publication Critical patent/WO2000028999A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouveau traitement de troubles moteurs tels que la dyskinésie tardive, les tics, le syndrome de la Tourette, le blépharospasme et autres dystonies focales. Le traitement proposé dans cette invention utilise des agents qui agissent simultanément comme des antagonistes des récepteurs du glutamate de type NMDA et des agonistes des récepteurs de GABA-A. Ces deux activités sont de préférence caractéristiques d'un agent unique, par exemple, de l'acamprosate. Il est également possible de combiner et d'administrer des agents distincts présentant ces activités. L'invention concerne aussi un troisième agent qui agit comme un agent bloquant les récepteurs de NMDA non compétitif ou un bloqueur des canaux ioniques qui augmente l'efficacité du traitement primaire. De préférence, le bloqueur des canaux ioniques est du magnésium. Il est également possible d'administrer du magnésium seul pour prévenir ou traiter des troubles moteurs.
PCT/US1999/027343 1998-11-18 1999-11-18 Procedes de traitement de la dyskinesie tardive et d'autres troubles moteurs Ceased WO2000028999A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17347/00A AU1734700A (en) 1998-11-18 1999-11-18 Methods of treating tardive dyskinesia and other movement disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/193,892 1998-11-18
US09/193,892 US6294583B1 (en) 1998-01-13 1998-11-18 Methods of treating tardive dyskinesia and other movement disorders

Publications (2)

Publication Number Publication Date
WO2000028999A2 WO2000028999A2 (fr) 2000-05-25
WO2000028999A3 true WO2000028999A3 (fr) 2000-07-20

Family

ID=22715448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027343 Ceased WO2000028999A2 (fr) 1998-11-18 1999-11-18 Procedes de traitement de la dyskinesie tardive et d'autres troubles moteurs

Country Status (3)

Country Link
US (3) US6294583B1 (fr)
AU (1) AU1734700A (fr)
WO (1) WO2000028999A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
ES2331905T3 (es) * 1999-04-28 2010-01-20 Bellus Health (International) Limited Composiciones y procedimientos para tratar la amiloidosis usando derivados sulfanato.
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
CA2440284A1 (fr) * 2001-03-08 2002-09-19 Emory University Antagonistes du recepteur nmda dependant du ph
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2005037215A2 (fr) * 2003-10-14 2005-04-28 Massachusetts Institute Of Technology Compositions et procedes destines a ameliorer la fonction cognitive et la plasticite synaptique
US20060183800A1 (en) * 2004-11-12 2006-08-17 Xianqi Kong Methods and fluorinated compositions for treating amyloid-related diseases
JP2008520647A (ja) * 2004-11-16 2008-06-19 ニューロケム （インターナショナル） リミテッド Ｃｎｓおよびアミロイド関連疾患治療のための化合物
CN101128421A (zh) 2004-12-22 2008-02-20 神经化学（国际）有限公司 治疗淀粉样相关疾病用的方法与组合物
EP2982372B1 (fr) * 2005-04-05 2020-08-05 Yale University Agents de modulation du glutamate pour le traitement de troubles mentaux
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US8510055B2 (en) * 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
WO2007125385A2 (fr) * 2005-12-22 2007-11-08 Neurochem (International) Limited Traitement de troubles rénaux, de la néphropathie diabétique et des dyslipidémies
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
AU2007337806A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
US20080249178A1 (en) 2007-03-22 2008-10-09 Guosong Liu Magnesium compositions and uses thereof for increasing lifespan
EA201070077A1 (ru) 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
CA2703831C (fr) * 2007-09-07 2013-04-16 Xenoport, Inc. Promedicaments de liberation de cyclisation d'ester de neopentyle sulfonyle d'ester d'acide pantoique complexe d'acamprosate, leurs compositions et procedes d'utilisation
WO2009033079A1 (fr) * 2007-09-07 2009-03-12 Xenoport, Inc. Promédicaments de libération de cyclisation d'ester de néopentyle sulfonyle d'ester d'acide pantoïque masqués extérieurement, leurs compositions et procédés d'utilisation
TW200932734A (en) * 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2010093859A1 (fr) 2009-02-12 2010-08-19 Indiana University Research & Technology Corporation Matériau et procédés de traitement de troubles du développement tels que l'autisme co-morbide et idiopathique
US8377473B2 (en) * 2009-07-01 2013-02-19 Magceutics, Inc. Slow release magnesium composition and uses thereof
US9000046B2 (en) 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
WO2012068161A1 (fr) 2010-11-15 2012-05-24 Agenebio, Inc. Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CA3123897C (fr) 2013-12-20 2024-02-06 Agenebio, Inc. Derives de benzodiazepine, compositions et procedes de traitement de la deficience cognitive
MA42624A (fr) 2015-06-19 2021-04-28 Agenebio Inc Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
CN105389460B (zh) * 2015-10-19 2018-09-11 苏华巍 中医体质甄别专家系统及其控制方法
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355043A (en) * 1979-05-23 1982-10-19 Les Laboratoires Meram Novel derivatives of 3-aminopropanesulfonic acid having a reinforced activity on membrane
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
US4233229A (en) 1978-01-03 1980-11-11 Gaf Corporation Preparation of salt-free N-acyl taurines
US4582705A (en) * 1982-07-12 1986-04-15 Leonard Primes Composition for detoxification
ATE94384T1 (de) 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
US5081703A (en) * 1990-06-27 1992-01-14 Pactel Corporation Satellite mobile communication system for rural service areas
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5262162A (en) 1991-09-06 1993-11-16 Merz & Co. Gmbh & Co. Cerebral-activating extract
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US5602150A (en) 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355043A (en) * 1979-05-23 1982-10-19 Les Laboratoires Meram Novel derivatives of 3-aminopropanesulfonic acid having a reinforced activity on membrane
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARTHOLINI G: "GABA receptor agonists: pharmacological spectrum and therapeutic actions", MED. RES. REV., vol. 5, no. 1, - 1895, pages 55 - 75, XP002108851 *
CORSI M ET AL: "Co-agonism in drug-receptor interaction: illustrated by the NMDA receptors", TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 17, no. 6, 1 June 1996 (1996-06-01), pages 220 - 222, XP004034563, ISSN: 0165-6147 *
GOZLAN H ET AL: "NMDA and GABAA receptors, NO and redox modulation. Fully oxidized NMDA receptors can still act as a source of NMDA receptor-driven plasticity", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 17, no. 5, 1 May 1996 (1996-05-01), pages 187-189, XP004034550 *
KARTZINEL R: "Pharmacology of Dystonia", CLIN NEUROPHARMACOL, vol. 2, 1977, pages 43 - 53, XP000882035 *
KENYON FE: "Magnesium Metabolism in Huntington's Chorea", EXCERPTA MEDICA - INTERNATIONAL CONGRESS SERIES - PROGRESS IN NEUROGENETICS XV, vol. 175, 1969, pages 597 - 599, XP000882149 *
RICHTER A ET AL.: "Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia", NEUROSCI LETT, vol. 133, no. 1, 1991, pages 57-60, XP002108849 *

Also Published As

Publication number Publication date
US20060128802A1 (en) 2006-06-15
AU1734700A (en) 2000-06-05
US20020013366A1 (en) 2002-01-31
US6294583B1 (en) 2001-09-25
US7498361B2 (en) 2009-03-03
WO2000028999A2 (fr) 2000-05-25
US7745493B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
WO2000028999A3 (fr) Procedes de traitement de la dyskinesie tardive et d'autres troubles moteurs
WO1999036064A3 (fr) Methodes de traitement de la dyskinesie tardive et autres perturbations des mouvements
WO2000056301A3 (fr) Traitement de l'etat de stress post-traumatique, de troubles obsessifs compulsifs et de troubles neuropsychiatriques associes
AP1869A (en) b2- Adrenergic receptor agonists.
IL169439A0 (en) Fluoroalkoxy-substituted 1,3 - dihydro-isoindolyl compounds and their pharmaceutical uses
IL125735A (en) Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
AU3632497A (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
EP0686629A3 (fr) Antagonistes des récepteurs de tachycinine cyclohexyliques
PL350408A1 (en) Antithrombotic use of glycine betaine
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
AU5144396A (en) Trisubstituted phenyl derivatives
MXPA97001884A (es) Composiciones para el tratamiento de trastornos enla piel.
PT1056454E (pt) Utilizacao de compostos macrolido para o tratamento do glaucoma
WO2003006893A3 (fr) Procedes inhibant la toxicite amyloide
WO2002004455A3 (fr) Tetrahydroisoquinoleines 4-phenyle substituees et leur utilisation therapeutique
WO2002028810A3 (fr) Nouveaux retinoides destines au traitement de l'emphyseme
CA2264063A1 (fr) Composes de cryptophycine
WO1999038532A3 (fr) Methodes de traitement et de prevention de la fibrose et de la sclerose
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
CA2132544A1 (fr) Antagonistes d'angiotensine ii utiles contre les troubles lies a une vitesse alteree de l'influx nerveux, particulierement dans le cas de la neuropathie diabetique
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
CA2347863A1 (fr) Traitement des affections de la retine
IL142220A0 (en) Method of treating viral hemorrhagic fever
WO2001092274A3 (fr) Inhibiteurs de la naaladase pour le traitement des affections de la retine

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 17347

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CH CN JP MX NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CH CN JP MX NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase